Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus CHILDREN S IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus CHILDREN S IBUPROFEN.
ANAPROX vs CHILDREN'S IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Category C
Category D/X
NSAID
NSAID